Curocell Inc. (KOSDAQ:372320)
South Korea
· Delayed Price · Currency is KRW 52,800
+800 (1.54%)
At close: Mar 6, 2026
Curocell Company Description
Curocell Inc., a cell gene therapy development company, engages in the development and manufacturing of pharmaceuticals.
It provides research and development services; and OVercome Immune Suppression (OVIS), a proprietary platform technology designed to get away from exhaustion induced by immune checkpoint receptors.
The company is also involved in the development of CD19 CAR-T treatment, blood cancer CAR-T, solid cancer CAR-T, and allogeneic CAR-T.
Curocell Inc. was founded in 2016 and is headquartered in Daejeon, South Korea.
Curocell Inc.
| Country | South Korea |
| Founded | 2016 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Kim Gunsoo |
Contact Details
Address: 11 Gukje Science 16-ro Daejeon, 34002 South Korea | |
| Phone | 82 4 2863 3698 |
| Website | curocellbtx.com |
Stock Details
| Ticker Symbol | 372320 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kim Gunsoo | Chief Executive Officer |
| Park Jin Kyong | Chief Financial Officer |